Clover has fully integrated biopharmaceutical drug manufacturing capabilities.

Our pilot GMP-compatible manufacturing facility in Chengdu has 150L in upstream bioreactor capacity to support preclinical research, IND-enabling and Phase I drug material. We have successfully completed IND-enabling production lots for SCB-808, as well as production lots for GLP testing for multiple products.

We are planning to initiate construction of our GMP manufacturing facility with 2 x 2,000L upstream single-use bioreactor capacity in 2H:2016 to support late-stage clinical trials and commercialization for multiple products.